Explore the Frontiers of Ubiquitin-Proteasome System

July 8, 2010 - PRLog -- PHILADELPHIA, PA – On August 23-25, 2010, industry scientists, CEOs, and academics will convene at Philadelphia’s Four Seasons Hotel for the Ubiquitin Drug Discovery and Diagnostics Conference to discuss the Next Big Thing (http://www.ubiquitinconference.com/pdf/Next_big_thing_in_Drug_development_UPS_2010-1.pdf) in drug discovery research—the ubiquitin pathway. Advances in oncology, infectious diseases, neurodegeneration, inflammation, diabetes, and muscle wasting will be covered.

The list of distinguished speakers includes:

•   Alfred L. Goldberg, PhD, Harvard Medical School; the father of protein-turnover
•   Kenneth Anderson, PhD, Dana-Farber Cancer Institute; an imminent clinical oncologist
•   Peter G. Smith, PhD, Millennium: The Takeda Oncology Co.; new cancer therapies
•   Ben Nicholson, PhD, Progenra Inc.; profiling cancer therapies
•   Michele Pagano, PhD, New York University; charting the function of E3 ligases
•   Jennifer Johnston, PhD, Elan Pharmaceuticals Inc.; targets in neurodegenerative disease

The agenda focuses on basic science, translational research and drug discovery within the ubiquitin pathway. It includes two technology-driven workshop sessions, four conference sessions, and three business roundtables facilitating collaboration across sectors.

In the business roundtables discussions, participants will explore new avenues of collaboration: “Biotech and Pharma Partnership: The new face of the industry;” “Academic and Industry Partnership: Translational research;” and the “Role of NIH in Drug Discovery”—Dr. Christopher P. Austin of the National Human Genome Research Institute will guide this final discussion.

Those interested in attending the conference should contact Varsha Luthra of VLI Research Inc. at 610-644-0585, ext. 319, or luthra@vli-research.com.

# # #

Varsha Luthra
Director, Ubiquitin Conferences
luthra@ubiquitinconferences.com
610-644-0585, ext. 319

www.ubiquitinconference.com